NasdaqCM - Delayed Quote USD

Immunome, Inc. (IMNM)

14.27 -0.39 (-2.66%)
At close: April 24 at 4:00 PM EDT
14.39 +0.12 (+0.84%)
After hours: April 24 at 5:59 PM EDT

Key Executives

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Clay B. Siegall Ph.D. President, CEO & Chairman -- -- 1961
Mr. Max Rosett Interim CFO & Executive VP of Operations -- -- 1990
Mr. Robert Lapetina Principal Accounting Officer -- -- 1975
Mr. Philip Roberts Chief Technical Officer -- -- --
Dr. Jack Higgins Ph.D. Chief Scientific Officer -- -- 1980
Ms. Sandra G. Stoneman Esq., J.D. Chief Legal Officer, General Counsel & Corporate Secretary 443.43k -- 1974
Mr. Bruce Turner M.D., Ph.D. Chief Strategy Officer -- -- 1964
Dr. Robert J. Lechleider M.D. Chief Medical Officer -- -- --
Mr. Kinney Horn Chief Business Officer -- -- 1975

Immunome, Inc.

18702 N. Creek Parkway
Suite 100
Bothell, WA 98011
United States
610-321-3700 https://immunome.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
55

Description

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Corporate Governance

Immunome, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 03, 2024 - May 07, 2024
Immunome, Inc. Earnings Call

Related Tickers

CGON CG Oncology, Inc.
36.05
-0.72%
 
ADXS Ayala Pharmaceuticals, Inc.
0.5400
0.00%
 
IMNN Imunon, Inc.
1.3000
-2.26%
 
NRIX Nurix Therapeutics, Inc.
13.75
-2.69%
 
CGEM Cullinan Therapeutics, Inc.
18.89
+13.32%
 
ADCT ADC Therapeutics SA
4.7800
-3.82%
 
LYRA Lyra Therapeutics, Inc.
5.23
+0.38%
 
DAWN Day One Biopharmaceuticals, Inc.
15.19
-8.71%
 
SYRE Spyre Therapeutics, Inc.
32.99
-3.68%
 
MRSN Mersana Therapeutics, Inc.
2.8800
-10.28%